BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Expands Offering to Include Boutique End-to-End CDMO Services

  • BiondVax’s CDMO services allow the company to partner with pharmaceutical companies to provide contract-based drug development and manufacturing services
  • BiondVax showcased its boutique end-to-end CDMO offering at the annual Biomed Conference in Tel Aviv in May
  • BiondVax’s cGMP biologics manufacturing facility in Jerusalem is fully equipped with state-of-the-art CDMO capabilities
  • The expansion of CDMO services will augment revenue and expand pharma contacts while still maintaining BiondVax’s core focus of NanoAb therapies for significant indications like COVID-19, psoriasis, asthma, and more

BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, recently showcased the expansion of its service to begin offering services as a contract development and manufacturing organization (“CDMO”). These CDMO services will allow BiondVax to partner with pharmaceutical companies to provide contract-based drug development and manufacturing services, leveraging its Good Manufacturing Practices (“GMP”) biologics manufacturing facility in Jerusalem.

In May, BiondVax showcased its boutique end-to-end CDMO services and expertise at a leading conference for international Life Science and HealthTech industries, the Biomed Conference, in Tel Aviv. The company’s CDMO services are designed to meet the needs of pharmaceutical and biotechnology companies of all sizes, with a commitment to providing customers with the highest levels of quality and service.

BiondVax’s CDMO offers a comprehensive range of services and assets, including:

  • cGMP manufacturing of biologics at FDA and EMA standards
  • State-of-the-art laboratories for manufacturing process development and scale-up
  • Deep pharma experience and leadership to help accelerate products forward

The company’s cGMP manufacturing suites include clean rooms for upstream fermentation, downstream purification, labeling and visual inspection. It has previously passed the required audits for Phase 3 clinical trial production and more – which can be found in BiondVax’s CDMO literature. (

“Offering CDMO services allows us to use our state-of-the-art facility to generate revenues and offset certain fixed costs while still using it for our NanoAbs,” BiondVax CEO Amir Reichman said in a year-end letter to stakeholders. In a March interview, he also said his team has proven experience with running pre-clinical trials, clinical trials, chemistry, manufacturing and controls [CMC], quality assistance — with everything working like an oiled machine ( “Also, the capacity and the capabilities are there.”

BiondVax’s NanoAbs, also known as VHH-antibodies, are alpaca-derived nanosized antibodies that exhibit multiple significant competitive advantages over existing antibody therapies. These advantages include stability at high temperatures, superior binding affinity, more effective and convenient routes of administration, and efficient production. The company is uniquely positioned to advance nanosized antibody innovation from R&D through commercialization.

BiondVax’s development of NanoAb therapies addresses diseases that are currently underserved by current treatments, with large growing markets. In addition to COVID-19, the growing market outlook for asthma and psoriasis supports BiondVax’s focus on creating efficient therapies for patients in these indications.

Recent company statements on its quarterly financial results noted that it has already begun R&D activities for an innovative NanoAb platform targeting immune system cytokines. The drug candidate development process will focus on cytokines such as IL-17 for their potential in treating psoriasis and psoriatic arthritis.

Adding the CDMO services will keep the team abreast of the latest industry developments and trends while building experience and generating revenue to support the company’s NanoAb focus – targeting COVID-19, psoriasis, asthma, and more.

For more information, visit the company’s website at

NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:

BioMedWire (BMW)
San Francisco, California
415.949.5050 Office

BioMedWire is part of the InvestorBrandNetwork.


Select A Month

Official NewsWire Relationships

BIO Informa DGE Dynamic Global Events DTC Healthcare Conference Kiasco Reasearch Nexus Conferences Octane

BioMedWire Currently Accepts



Bitcoin Cash

Bitcoin Cash





USD Coin

USD Coin

Contact us: 415.949.5050